Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, May 22, 2012
Technology Networks
 
Register | Sign in
Home Page
  Contact Us


Address

Technology Networks Limited
Woodview
Bull Lane Industrial Estate
SUDBURY
CO10 0FD
UK

Tel: +44 (0) 1787 31 92 34
Fax: +44 (0) 1787 31 92 35

Email

For Editorial and Press Releases contact: Ashley Board

For Advertising contact: Kelly Giles

For Technical Support contact: The Webmaster

For Contra Deals contact: Karen Saunders

Scientific News
Promethera Biosciences Treats First Patients with Promethera® HepaStem
Phase I/II study designed to evaluate the ability of liver progenitor cells to restore a missing enzyme function in liver-based metabolic diseases.
Mucosis Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans
Mimopath®-based vaccines are able to produce balanced immune responses in both circulating blood and the respiratory tract.
New Muscular Dystrophy Treatment Approach Developed Using Human Stem Cells
New process makes the production of human muscle cells from stem cells efficient and effective.
Mucosis Announces Publication of Preclinical Data of Novel Influenza Vaccines
Mucosally administered Mimopath-based influenza vaccine protects against both homologous and heterologous challenge.
Idera Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial
IMO-2055 to be used in treatment of patients with advanced head and neck cancer.
Agent Reduces Autism-like Behaviors in Mice
Boosts sociability, quells repetitiveness - NIH study.
Adocia Reports Positive Phase II Clinical Results for the Treatment of Diabetic Foot Ulcer
Adocia’s spray formulation of PDGF-BB, combined with BioChaperone®, has been evaluated versus Regranex®, gel of PDGF-BB.
New Classification Criteria Released for Research on Sjogren's Syndrome
NIH-supported alliance validates classification criteria for condition based on objective tests.
NIH Study to Test Treatment for Fatty Liver Disease in Children
NIH researchers to find out fatty liver disease diagnosis with cysteamine in CyNCh trial.
Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat
Drug studied in combination with Lapatinib in HER2-positive metastatic breast cancer.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Get The App
Go to LabTube.tv
Go to ePosters.net